Prevalence and subtypes of mild cognitive impairment in Parkinson's disease

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Lawrence, Blake J ^a   Gasson, Natalie ^a   Loftus, Andrea M ^a  

^a CURTIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; CLASSIFICATION; CLINICAL TRIAL; COGNITIVE DEFECT; FEMALE; HUMAN; MALE; MIDDLE AGED; PARKINSON DISEASE; PREVALENCE; PSYCHOLOGY;

AGED; COGNITIVE DYSFUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PREVALENCE;

EID: 84988859649     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep33929     Document Type: Article

References (62)

1. Williams-Gray, C. H. et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry. 84, 1258-1264 (2013).
2. Litvan, I. et al. MDS task force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord. 26, 1814-1824 (2011).
3. Cosgrove, J., Alty, J. E., & Jamieson, S. Cognitive impairment in Parkinson's disease. Postgrad Med J. 91, 212-220 (2015).
4. Kehagia, A. A., Barker, R. A., & Robbins, T. W. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol. 9, 1200-1213 (2010).
5. Muslimovic, D., Schmand, B., Speelman, J. D., & De Haan, R. J. Course of cognitive decline in Parkinson's disease: a meta-Analysis. JINS. 13, 920-932 (2007).
6. Pedersen, K. F., Larsen, J. P., Tysnes, O., & Alves, G. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA. 70, 580-586 (2013).
7. Williams-Gray, C. H. et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain. 132, 2958-2969 (2009).
8. Litvan, I. et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord. 27, 349-356 (2012).
9. Petersen, R. C. Mild cognitive impairment. N Engl J Med. 364, 2227-2234 (2011).
10. Goldman, J. G. et al. Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease. Mov Disord. 28, 1972-1979 (2013).
11. Marras, C. et al. Measuring mild cognitive impairment in patients with Parkinson's disease. Mov Disord. 28, 626-633 (2013).
12. Cholerton, B. A. et al. Evaluation of mild cognitive impairment subtypes in Parkinson's disease. Mov Disord. 29, 756-764 (2014).
13. Hely, M. A., Reid, W. G. J., Adena, M. A., Halliday, G. M., & Morris, J. G. L. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord, 23, 837-844 (2008).
14. Kline, P The Handbook of Psychological Testing, 2nd ed. (Routledge 1999).
15. Caviness, J. N. et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord. 22, 1272-1277 (2007).
16. Goldman, J. G., Weis, H., Stebbins, G., Bernard, B., & Goetz, C. G. Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. Mov Disord. 27, 1129-1136 (2012).
17. Biundo, R. et al. Diagnostic and screening power of neuropsychological testing in detecting mild cognitive impairment in Parkinson's disease. J Neural Transm. 120, 627-633 (2013).
18. Liepelt-Scarfone, I. et al. Influence of different cut-off values on the diagnosis of mild cognitive impairment in Parkinson's disease. Parkinsons Dis. 2011, 1-7 (2011).
19. Muslimovic, D., Post, B., Speelman, J. D., & Schmand, B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology. 65, 1239-1245 (2005).
20. Loftus, A. M. et al. Retrospective assessment of Movement Disorder Society Criteria for mild cognitive impairment in Parkinson's disease. JINS. 21, 137-145 (2015).
21. Geurtsen, G. J. et al. Parkinson's disease mild cognitive impairment: application and validation of the criteria. J Parkinsons Dis. 4, 131-137 (2014).
22. Svenningsson, P., Westman, E., Ballard, C., & Aarsland, D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 11, 697-707 (2012).
23. Compta, Y. et al Lewy-And Alzheimer-Type pathologies in Parkinson's disease dementia: which is more important? Brain. 134, 1493-1505 (2011).
24. Nombela, C. et al. Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain. 10, 2743-2758 (2014).
25. Kehagia, A. A., Barker, R. A., & Robbins, T. W. Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis. Neurodegener Dis. 11, 79-92 (2013).
26. Kudlicka, A., Clare, L., & Hindle, J. V. Executive functions in Parkinson's disease: systematic review and meta-Analysis. Mov Disord. 26, 2305-2315 (2011).
27. Lezak, M., Howieson, D., & Loring, D Neuropsychological Assessment, 5th ed. (Oxford University Press 2012).
28. Stuss, D T., & Alexander, M. P. Is there a dysexecutive syndrome? Philos Trans R Soc Lond B Biol Sci. 362 901-915 2007).
29. Smith, E. E., & Jonides, J. Storage and executive processes in the frontal lobes. Science. 283, 1657-1661 (1999).
30. Zelazo, P. D., & Carlson, S. M. Hot and cool executive function in childhood and adolescence: development and plasticity. Child Dev Per. 6, 354-360 (2012).
31. Elgh, E. et al. Cognitive function in early Parkinson's disease: a population-based study. Eur J Neurol. 16, 1278-1284 (2009).
32. Hu, M. et al. Predictors of cognitive impairment in an early stage Parkinson's disease cohort. Mov Disord. 29, 351-359 (2014).
33. Fahn, S. et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 351, 2498-2508 (2004).
34. Dujardin, K. et al. Cognitive disorders in Parkinson's disease: confirmation of a spectrum of severity. Parkinsonism Relat Disord. 21, 1299-1305 (2015).
35. Strauss, E., Sherman, E., & Spreen, O A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. (Oxford University Press, 2006).
36. Mitrushina, M., Boone, K. B., Razani, J., & Delia, L. F. Handbook of Normative Data for Neuropsychological Assessment. (Oxford University Press, 2005).
37. Goldman, J. G., & Weintraub, D. Advances in the treatment of cognitive impairment in Parkinson's disease. Mov Disord. 30, 1471-1489 (2015).
38. Mamikonyan, E., Xie, S. X., Melvin, E., & Weintraub, D. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebocontrolled study. Mov Disord. 30, 912-918 (2015).
39. Frakey, L., & Friedman, J A-31 the effects of rasagiline on cognition in mild to moderate stage Parkinson's disease, a double-blind placebo controlled study. Arch Clin Neuropsychol. 29 514-514 2014).
40. Hindle, J. V., Petrelli, A., Clare, L., & Kalbe, E. Nonpharmacological enhancement of cognitive function in Parkinson's disease: a systematic review. Mov Disord. 28, 1034-1049 (2013).
41. Pal, E., Nagy, F., Aschermann, Z., Balazs, E., & Kovacs, N. The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson's disease: a randomized, double-blind, placebo-controlled study. Mov Disord. 25, 2311-2317 (2010).
42. Paris, A. P. et al. Blind randomized controlled study of the efficacy of cognitive training in Parkinson's disease. Mov Disord. 26, 1251-1258 (2011).
43. Brandt, J., Spencer, M., & Folstein, M. The telephone interview for cognitive status. Cog Behav Neurol. 1, 111-118 (1988).
44. Benton, A. L. Differential behavioral effects in frontal lobe disease. Neuropsychologia. 6, 53-60 (1968).
45. Wechsler, D Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV). (Pearson 2008).
46. Golden, C. J., & Freshwater, S. Stroop Colour and Word test: Revised Examiner's Manual. (Stoelting Co, 2002).
47. Brandt, J., & Benedict, R H. Hopkins Verbal Learning Test-Revised: Professional Manual. (Psychological Assessment Resources, 2001).
48. Wilson, B., Cockburn, J., Baddeley, A., & Hiorns, R. The development and validation of a test battery for detecting and monitoring everyday memory problems. J Clin Exp Neuropsychol. 11, 855-870 (1989).
49. Benton, A L., Hamsher, K. D., & Sivan, A. B. Multilingual Aphasia Examination: Manual of Instructions, 3rd ed. (AJA 1994).
50. Hooper, H Hooper Visual Organisation Test: Manual. (Western Psychological Services, 1983).
51. Kaplan, E., Goodglass, H., & Weintraub, S. Boston Naming Test, 2nd ed. (Pro-Ed, 2001).
52. Pagonabarraga, J. et al. Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease. Mov Disord. 23, 998-1005 (2008).
53. Folstein, M. F., Folstein, S. E., & McHugh, P. R. 'Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 12, 189-198 (1975).
54. Hennessy, M., & Mackenzie, B. AUSNART: the development of an Australian version of the NART. The 18th Annual Brain Impairment Conference, Hobart, Australia (1995).
55. Goetz, C. G. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 23, 2129-2170 (2008).
56. Tomlinson, C. L. et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 25, 2649-2653 (2010).
57. Copeland, J. N., Lieberman, A., Oravivattanakul, S., & Troster, A. I. Accuracy of patient and care partner identification of cognitive impairments in Parkinson's disease-mild cognitive impairment. Mov Disord, 31, 693-698 (2016).
58. Howell, D Statistical Methods for Psychology, 8th ed. (Cengage Learning 2013).
59. Field, A Discovering statistics using IBM SPSS statistics, 4th ed. (Sage 2013).
60. Cronbach, L. J. Coefficient alpha and the internal structure of tests. Psychometrika. 16, 297-334 (1951).
61. Anastasi, A., & Urbina, S Psychological Testing, 7th ed. (Prentice Hall 1997).
62. Cortina, J. M. What is coefficient alpha? An examination of theory and applications. J Appl Psychol. 78, 98-104 (1993).